Selley D E, Sim L J, Xiao R, Liu Q, Childers S R
Department of Physiology and Pharmacology, Bowman Gray School of Medicine, Wake Forest University, Winston-Salem, North Carolina 27157, USA.
Mol Pharmacol. 1997 Jan;51(1):87-96. doi: 10.1124/mol.51.1.87.
G protein activation by different mu-selective opioid agonists was examined in rat thalamus, SK-N-SH cells, and mu-opioid receptor-transfected mMOR-CHO cells using agonist-stimulated guanosine-5'-O-(gamma-thio)-triphosphate ([35S]GTP gamma S) binding to membranes in the presence of excess GDP. [D-Ala2, N-MePhe4, Gly5-ol]Enkephalin (DAMGO) was the most efficacious agonist in rat thalamus and SK-N-SH cells, followed by (in rank order) fentanyl = morphine > > buprenorphine. In mMOR-CHO cells expressing a high density of mu receptors, no differences were observed among DAMGO, morphine or fentanyl, but these agonists were more efficacious than buprenorphine, which was more efficacious than levallorphan. In all three systems, efficacy differences were magnified by increasing GDP concentrations, indicating that the activity state of G proteins can affect agonist efficacy. Scatchard analysis of net agon stimulated [35S]GTP gamma S binding revealed two major components responsible for agonist efficacy differences. First, differences in the KD values of agonist-stimulated [35S]GTP gamma S binding between high efficacy agonists (DAMGO, fentanyl, and morphine) and classic partial agonists (buprenorphine and levallorphan) were observed in all three systems. Second, differences in the Bmax value of agonist-stimulated [35S]GTP gamma S binding were observed between DAMGO and morphine or fentanyl in rat thalamus and SK-N-SH cells and between the high efficacy agonists and buprenorphine or levallorphan in all three systems. These results suggest that mu-opioid agonist efficacy is determined by the magnitude of the receptor-mediated affinity shift in the binding of GTP (or[35S]GTP gamma S) versus GDP to the G protein and by the number of G proteins activated per occupied receptor.
利用在过量GDP存在的情况下激动剂刺激的鸟苷-5'-O-(γ-硫代)-三磷酸([35S]GTPγS)与膜结合的方法,在大鼠丘脑、SK-N-SH细胞以及转染了μ-阿片受体的mMOR-CHO细胞中检测了不同μ-选择性阿片类激动剂对G蛋白的激活作用。[D-丙氨酸2,N-甲基苯丙氨酸4,甘氨酸5-醇]脑啡肽(DAMGO)是大鼠丘脑和SK-N-SH细胞中最有效的激动剂,其次(按顺序)是芬太尼 = 吗啡 >> 丁丙诺啡。在表达高密度μ受体的mMOR-CHO细胞中,未观察到DAMGO、吗啡或芬太尼之间存在差异,但这些激动剂比丁丙诺啡更有效,而丁丙诺啡比烯丙左啡诺更有效。在所有这三个系统中,通过增加GDP浓度可放大效能差异,这表明G蛋白的活性状态可影响激动剂效能。对净激动剂刺激的[35S]GTPγS结合进行Scatchard分析,揭示了导致激动剂效能差异的两个主要因素。首先,在所有这三个系统中均观察到高效能激动剂(DAMGO、芬太尼和吗啡)与经典部分激动剂(丁丙诺啡和烯丙左啡诺)之间激动剂刺激的[35S]GTPγS结合的KD值存在差异。其次,在大鼠丘脑和SK-N-SH细胞中观察到DAMGO与吗啡或芬太尼之间激动剂刺激的[35S]GTPγS结合的Bmax值存在差异,并且在所有这三个系统中高效能激动剂与丁丙诺啡或烯丙左啡诺之间也存在差异。这些结果表明μ-阿片类激动剂的效能由受体介导的GTP(或[35S]GTPγS)与GDP结合时亲和力变化的幅度以及每个被占据受体激活的G蛋白数量所决定。